MONTREAL (CANADA) – May 12, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announced that François Ravenelle, PhD, Chief Executive Officer and Glenn D. Crater, MD, FCCP, Chief Medical Officer, will take part to the Presenting Company Class of 2022 at Bio€quity Europe. Details are as follows:
MAY 16-18, 2022
François Ravenelle and Glenn Crater will be available for 1-on-1 meetings with the investment community during Bio€quity Europe.
Online Presentation by Inversago: 12 min. corporate presentation by Inversago’s CEO available to delegates as of today on partneringONE website.
MAY 23-24, 2022
Event Platform: partneringONE website
1-on-1 Virtual Meetings: Professional investors will have the opportunity to request 1-on-1 virtual meetings with Inversago Pharma.
About Bio€quity Europe 2022
Organized by BioCentury and EBD Group, Bio€quity Europe 2022 is Europe’s premier international showcase for financial dealmakers and biopharma executives to meet 100+ rising biotechs. For information and registration, please visit: conferences.biocentury.com/bioequity-europe.
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).
– 30 –
François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma Inc.